(Total Views: 384)
Posted On: 02/26/2020 5:22:00 PM
Post# of 154064
Gilead to initiate two Phase 3 studies for coronavirus
Gilead Sciences (NASDAQ:GILD) +2.5% is starting the studies for the safety and efficacy of remdesivir in adults with Covid-19, or novel coronavirus.
Starting in March, the studies will enroll about 1,000 patients in medical centers primarily located in Asia and other countries with a high number of diagnosed coronavirus cases.
One study will randomize 400 patients with severe Covid-19 to receive either five or 10 days of remdesivir. The other study includes 600 moderate patients receiving the same dosage or standard of care alone
Gilead Sciences (NASDAQ:GILD) +2.5% is starting the studies for the safety and efficacy of remdesivir in adults with Covid-19, or novel coronavirus.
Starting in March, the studies will enroll about 1,000 patients in medical centers primarily located in Asia and other countries with a high number of diagnosed coronavirus cases.
One study will randomize 400 patients with severe Covid-19 to receive either five or 10 days of remdesivir. The other study includes 600 moderate patients receiving the same dosage or standard of care alone
(0)
(0)
